HealthQuill Drugs
Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and commercialising of the Chinese company’s “triple G” weight-loss candidate.
Drugs Medical Pharma

Novo Nordisk in $2b deal with Chinese firm for ‘triple-G’ obesity drug

HQ Team February 25, 2025: Novo Nordisk has inked a $2 billion licensing pact with United Laboratories International for the development, manufacturing and.

Read More
Progress in slowing child mortality and stillbirth deaths has received a severe blow due to funding cuts and shortages, with 1.9 million children dying in 2023 on account of stillbirths.
Drugs Health Pharma

Funding cuts ‘severely’ bleeding UN’s child survival, stillbirth programs

HQ Team March 25, 2025: Progress in slowing child mortality and stillbirth deaths has received a severe blow due to global funding cuts.

Read More
Nova Nordisk's Ozempic has changed he weight loss landscape
Drugs Pharma

Brazil’s pharma giant Hypera to launch generic Ozempic in 2026

Bharti Jayshankar March 24, 2025: Brazilian pharmaceutical giant Hypera announced plans to introduce a generic version of semaglutide—the active ingredient in Novo Nordisk’s.

Read More
Eight people have died in Rwanda due to Marburg virus disease and 26 others were confirmed to be infected by the illness — the first such in the eastern-central African nation.
Drugs Research

Study uncovers protein’s dual role in sepsis, offering new treatment hope

HQ Team March 18, 2025: Sepsis, a life-threatening response to infection that triggers organ failure, claims over 11 million lives worldwide annually, according.

Read More
The UNICEF and the private-public partnership Gavi Vaccine Alliance will roll out its malaria vaccine for the first time in nine African countries to fight one of the deadliest diseases in the continent, according to the WHO.
Drugs Health

Abrupt cessation of US funds could lead to 3 million HIV-related deaths: WHO

HQ Times March 18, 2025: The strides made in disease containment and eradication such as malaria, HIV, and tuberculosis in the last 20.

Read More
Drugs Research

Celon Pharma’s pill shows promise in reducing dyskinesia in Parkinson’s trial

HQ Team March 17, 2025: Celon Pharma’s human trial with PDE10A inhibitor, CPL’36, has achieved statistically significant reductions in involuntary movements caused by.

Read More
Eneboparatide (AZP-3601) meets its primary goal in the CALYPSO Phase III trial, offering hope for chronic hypoparathyroidism patients.
Drugs

Eneboparatide succeeds in Phase III trial for chronic hypoparathyroidism

HQ Team March 17, 2025: The Phase III CALYPSO trial, led by Alexion, AstraZeneca Rare Disease, has shown promising results for eneboparatide (AZP-3601),.

Read More
ADHD medicine
Drugs

UN narcotics agency places 6 new substances under international control

March 14, 2025 –The United Nations Commission on Narcotic Drugs (CND) has decided to place five new psychoactive substances and one medicine under.

Read More
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Pharma

Johnson & Johnson ends late-stage trial of depression drug aticaprant

HQ Team March 7, 2025: Johnson & Johnson is discontinuing the Phase 3 VENTURA clinical trial of its experimental depression drug aticaprant after.

Read More
Novo Nordisk will pay Gensaic, Inc., a biotechnology company, an upfront payment of $354 million for the latter’s technology to discover tissue-targeting molecules.
Drugs Medical Pharma

Novo Nordisk to pay US-based Gensaic $354 million upfront in licensing deal

HQ Team March 5, 2025: Novo Nordisk will pay Gensaic, Inc., a biotechnology company, an upfront payment of $354 million for the latter’s.

Read More